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Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting
with Stage IV disease do not survive past 5 years. We present updated efficacy and
safety analyses in high‐risk patient subgroups, defined by Stage IV disease or
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International Prognostic Score (IPS) of 4–7, enrolled in the ECHELON‐1 study that
compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine
(A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as
first‐line therapy after a median follow‐up of 37.1 months. Among patients treated
with A +AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an
IPS of 4–7. Patients with Stage IV disease treated with A + AVD showed consistent
improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723;
95% confidence interval [CI], 0.537–0.973; p = 0.032). Similar improvements were
seen in the subgroup of patients with IPS of 4–7 (HR, 0.588; 95% CI, 0.386–0.894;
p = 0.012). Themost common adverse events (AEs) in A+AVD‐treated versus ABVD‐
treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and
neutropenia (71% vs. 55%); in patients with IPS of 4–7, the most common AEs were
peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neu-
tropenia (23%vs. 9%), respectively. Patients in high‐risk subgroups did not experience
greater AE incidence or severity than patients in the total population. This updated
analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients.
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1 | INTRODUCTION
Despite advances in recent years, advanced‐stage classical Hodgkin
lymphoma (cHL) treated with doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD) relapses or becomes refractory in 25%–30%
of patients.1–3 Bleomycin, etoposide, doxorubicin hydrochloride,
cyclophosphamide, vincristine, procarbazine, and prednisone (BEA-
COPPesc) results in higher initial disease control in younger, fit pa-
tients but at the expense of significantly higher acute and late
toxicity, secondary malignancies, and treatment‐related mortality.4–6
Patients with Stage IV disease have a relatively poor prognosis, with
an overall survival (OS) rate of approximately 76% at 5 years.7 The
development of more‐effective yet tolerable treatment options for
patients with advanced‐stage cHL, especially those with high‐risk
characteristics, is warranted.
Brentuximab vedotin (BV) is a novel antibody‐drug conjugate
targeting the CD30 antigen expressed on Hodgkin Reed–Sternberg
cells. Across a range of trials, BV has been shown to induce durable
remissions in patients with cHL who relapsed after autologous stem
cell transplant. In the pivotal trial, BV treatment resulted in a complete
response (CR) rate of 34% (95% confidence interval [CI], 25.2–44.4)
and objective response rate of 75% (95% CI, 64.9–82.6) per inde-
pendent review committee.8 Notably, a subset of 15 patients from this
study achieved complete remission and maintained their response
for ≥5 years; of these, six patients received consolidative allogeneic
stem cell transplant, and nine patients received no further therapy
after completing BV treatment.9 The use of BV as a consolidation
treatment option for adult patients with cHL at high risk of relapse or
progression following autologous hematopoietic stem cell transplant
resulted in improved progression‐free survival (PFS) compared with
placebo.10 In a Phase 1 dose‐escalation study of BV in combination
with AVD, 24 of 25 patients (96%) with newly diagnosed cHL achieved
complete remission.11 Based on these findings, a global, multicenter,
open‐label, randomized, phase 3 clinical study, the ECHELON‐1 trial,
was conducted to assess the efficacy and safety of a therapeutic
combination of BV plus AVD (A + AVD) versus ABVD as first‐line
therapy in advanced stage (III and IV) cHL.12
At a median follow‐up of 24.6 months, primary analyses of
ECHELON‐1 showed a 23% risk reduction for modified PFS (hazard
ratio [HR] for progression, death, or modified progression event,
0.77; 95% CI, 0.60–0.98; p = 0.035) in patients receiving A + AVD,
with 2‐year modified PFS rates of 82.1% (95% CI, 78.8%–85.0%) in
patients receiving A + AVD and 77.2% (95% CI, 73.7%–80.4%) in
those receiving ABVD.12 At the primary analysis, 28 deaths had
occurred with A + AVD and 39 with ABVD (HR for interim OS, 0.72;
95% CI, 0.44–1.17; p = 0.19).12
This post hoc analysis includes the updated 3‐year efficacy and
safety of A + AVD compared with ABVD (data cutoff, 15 October
2018; median follow‐up for PFS was 37.1 months) in a prespecified
high‐risk patient subgroup presenting at baseline with Stage IV dis-
ease or an International Prognostic Score (IPS) of 4–7.
2 | METHODS
2.1 | Patient eligibility and study design
Full details of the ECHELON‐1 study (ClinicalTrials.gov identifier
NCT01712490; EudraCT 2011‐005450‐60) have been pub-
lished.12,13 Briefly, we recruited patients aged ≥18 years with his-
tologically confirmed cHL (Ann Arbor stage III or IV) who had not
been previously treated with systemic chemotherapy or radiotherapy
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and had an Eastern Cooperative Oncology Group performance status
of 0–2 (Figure S1).
Patients were randomized 1:1 to receive A + AVD or ABVD
intravenously on Days 1 and 15 of each 28‐day cycle for up to six
cycles, with stratification by IPS (0–1, 2–3, or 4–7) and region
(Americas, Asia, or Europe).
ECHELON‐1 was conducted in accordance with regulatory re-
quirements; the protocol was approved by the institutional review
boards and ethics committees at each registered site. Written
informed consent per the local ethics committee was mandatory
before enrollment. This study was conducted according to the
guideline of the International Conference on Harmonisation Good
Clinical Practice.
2.2 | Endpoints
The primary endpoint was modified PFS per an independent review
facility (IRF), defined as the time to disease progression, death, or
modified progression event (with the latter defined as evidence of
non‐CR after completion of frontline therapy according to review by
an independent committee, followed by subsequent anticancer
therapy).12 Non‐CR was defined by an end‐of‐therapy positron
emission tomography (PET) scan with a Deauville five‐point scale
score of 3–5. The key secondary endpoint was OS (time from date of
randomization to date of death). These endpoints were specified in
the primary analysis (data cutoff, 20 April 2017).
PFS per investigator for the intent‐to‐treat (ITT) population was
a preplanned supportive analysis. At a median follow‐up of 37.1
months, we report extended follow‐up of PFS (defined as time to
progression or death) per the investigator for patients with Stage IV
disease or an IPS of 4–7. Following the primary analysis, the protocol
did not require investigators to submit further information to the IRF.
2.3 | Statistical analysis
Stratified log‐rank testing was used to compare modified PFS and OS
between the two treatment arms as part of the primary analysis and
key secondary analysis in the ITT population. Stratification factors
included geographic region and IPS at baseline. HRs, along with 95%
CIs, were estimated using a stratified Cox model, with treatment as
the explanatory variable.
In the primary analysis, a broad number of prespecified subgroup
analyses was performed, including region, extranodal site involve-
ment, IPS, sex, disease stage, and age.12 The present subgroup ana-
lyses for PFS used unstratified Cox models and unstratified log‐rank
testing and included the following subgroups: stage (III vs. IV) and IPS
(0–1 vs. 2–3 vs. 4–7).
Extended follow‐up of modified PFS per IRF was not feasible
following the primary analysis because the protocol did not require
investigators to submit further information to the IRF. Additional
supportive analyses were performed to evaluate the treatment
effects on PFS per the investigator and OS in these two prespecified
groups. An unstratified Cox proportional hazards model was used to
estimate HRs. All p values from subgroup analyses were based on
unstratified log‐rank tests and are for descriptive purposes only,
without multiplicity adjustment.
Safety was summarized for type, incidence, severity, seriousness,
and relatedness of adverse events (AEs), as well as type, incidence,
and severity of laboratory abnormalities. AEs were coded using the
Medical Dictionary for Regulatory Activities (MedDRA) version 10.1
or higher. Laboratory values were graded in accordance with the
National Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0. Statistical analyses were performed using SAS
version 9.1 or higher (SAS Institute).
3 | RESULTS
A total of 1334 patients (ITT population) at 218 sites in 21 countries
were randomly assigned to receive A + AVD (n = 664) or ABVD
(n = 670). The data cutoff date for the present updated analysis was
15 October 2018, with a median follow‐up of 37.1 months and pri-
mary data from 20 April 2017 at a median follow‐up of 24.6 months.
Overall, 64% of patients had Stage IV disease (64% in the A + AVD
arm; 63% in the ABVD arm); 26% had an IPS of 4–7 (25% in the
A + AVD arm; 27% in the ABVD arm). Baseline characteristics were
balanced between the two treatment arms and are presented in
Table 1 for patients with Stage IV disease (n = 846) and in Table S1
for those with an IPS of 4–7 (n = 347).
In patients with Stage IV disease at the time of the primary
analysis, there was a 28.9% reduction in the risk of a modified PFS
per IRF event in the A + AVD arm compared with the ABVD arm (HR,
0.711; 95% CI, 0.529–0.956; p = 0.023). The modified PFS rate per
IRF at 2 years was 82.0% (95% CI, 77.8%–85.5%) in the A + AVD arm
compared with 75.3% (95% CI, 70.6%–79.3%) in the ABVD arm
(Figure 1A). An interim analysis of OS indicated that patients with
Stage IV disease who received A + AVD had an almost 50% reduction
in the risk of death (14/425 [3.3%]) compared with those who
received ABVD (26/421 [6.2%]), with an HR of 0.507 (95% CI, 0.265–
0.971; p = 0.037); the estimated 2‐year OS rate was 97.4% (95% CI,
95.3%–98.5%) in the A + AVD arm and 93.4% (95% CI, 90.3%–
95.6%) in the ABVD arm (Figure 1B). In patients with an IPS of 4–7, a
44.2% reduction was observed in the risk of a modified PFS per IRF
event in the A + AVD arm compared with the ABVD arm (HR, 0.558;
95% CI, 0.357–0.874; p = 0.010). The modified PFS per IRF rate at 2
years was 77.0% (95% CI, 69.5%–82.9%) in the A + AVD arm
compared with 69.2% (95% CI, 61.5%–75.8%) in the ABVD arm
(Figure 2A). Among patients with an IPS of 4–7, the interim analysis
of OS showed a 48.1% reduction in risk of death in patients who
received A + AVD (11/169 [6.5%]) compared with those who
received ABVD (22/178 [12.4%]), with an HR of 0.519 (95% CI,
0.252–1.070; p = 0.070; Figure 2B).
The benefit of A + AVD versus ABVD was maintained in an
analysis of PFS per investigator with median follow‐up of 3 years (HR,
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0.70; 95%CI, 0.55–0.90; p= 0.005). Patientswith Stage IV disease also
benefited from treatmentwith A+AVD versus ABVD (HR, 0.723; 95%
CI, 0.537–0.973; p = 0.032) with a 3‐year PFS rate of 81.8% (95% CI,
77.6%–85.3%) in the A + AVD arm and 74.9% (95% CI, 70.2%–78.9%)
in the ABVD arm (a difference of 6.9%; Figure 3).
Patients with Stage IV disease experienced benefit with A + AVD
across the majority of subgroups that were predefined for the ITT
population in ECHELON‐1 (Figure 4). Notably, the PFS benefit per
investigator at 3 years with A + AVD over ABVD was maintained in
both younger (<60 years) and older (≥60 years) patients (HR, 0.760;
95% CI, 0.542–1.067 for patients aged <60 years; HR, 0.685; 95% CI,
0.367–1.278 for patients aged ≥60 years). In addition, the PFS
benefit per investigator at 3 years with A + AVD over ABVD was
noted in both PET2‐negative patients (A + AVD n = 379; ABVD
n = 358) and ‐positive patients (A + AVD n = 34; ABVD n = 42) with
Stage IV disease (HR, 0.732; 95% CI, 0.520–1.031 for PET2‐negative
patients; HR, 0.727; 95% CI, 0.366–1.445 for PET2‐positive patients).
Patients with an IPS of 4–7 had results consistent with those in
patients with Stage IV disease. The PFS per investigator at 3 years
showed an improvement in the A + AVD arm compared with the
ABVD arm, with an HR of 0.588 (95% CI, 0.386–0.894; p = 0.012;
Figure 5). The 3‐year PFS rate in patients with an IPS of 4–7 was
79.6% (95% CI, 72.4%–85.1%) in the A + AVD arm and 65.7% (95%
CI, 57.8%–72.4%) in the ABVD arm. The PFS benefit per investigator
at 3 years with A + AVD over ABVD were noted in both PET2‐
negative patients (A + AVD n = 144; ABVD n = 148) and ‐positive
patients (A + AVD n = 16; ABVD n = 19) with an IPS of 4–7 (HR,
0.545; 95% CI 0.331–0.898 for PET2‐negative; HR, 0.510; 95% CI,
0.190–1.365 in PET2‐positive patients).
3.1 | Safety
Safety data are from the primary analysis (data cutoff date, 20 April
2017; median follow‐up was 24.6 months), with the exception of
peripheral neuropathy (PN) and secondary malignancy data, which
had a median follow‐up of 37.1 months (data cutoff, 15 October
2018). During the study, most patients with Stage IV disease
experienced ≥1 treatment‐related AE, regardless of treatment
(Table 2). Safety results in patients with Stage IV disease and IPS of
4–7 were consistent with safety results reported in the overall
population and did not change with longer observation.12 Among
TAB L E 1 Demographic and clinical
characteristics of patients with Stage IV
disease at baseline
Characteristic A + AVD (n = 425) ABVD (n = 421)




Age category, n (%)
<45 years 292 (69) 260 (62)
45–59 years 82 (19) 94 (22)
≥60 years 51 (12) 67 (16)
IPS risk factors, n (%)
0–1 55 (13) 43 (10)
2–3 225 (53) 227 (54)
4–7 145 (34) 151 (36)
Bone marrow involvement at diagnosis, n (%)
Yes 142 (33) 140 (33)
No 271 (64) 276 (66)
Unknown 12 (3) 5 (1)
ECOG performance status, n (%)
0 221 (52) 217 (52)
1 184 (43) 181 (43)
2 20 (5) 22 (5)
Patients with any B symptom, n (%) 276 (65) 256 (61)
Abbreviations: A + AVD, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine;
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ECOG, Eastern Cooperative Oncology
Group; IPS, International Prognostic Score , .
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patients with Stage IV disease, drug‐related AEs occurred in 96% in
the A + AVD arm and 93% in the ABVD arm. Patients with Stage IV
disease receiving A + AVD experienced more grade ≥3 treatment‐
emergent AEs (83% vs. 67%), grade ≥3 drug‐related AEs (79% vs.
61%), and serious AEs (40% vs. 28%) than those receiving ABVD,
respectively, but fewer of those receiving A + AVD died within 30
days of the last dose of frontline therapy (5 vs. 8 patients,
respectively; Table 2). Patients with an IPS of 4–7 at baseline had
similar safety profiles to those with Stage IV disease and the overall
population (Table S2).
Consistent with results in the overall population, more patients
with Stage IV disease in the A + AVD arm experienced any‐grade
treatment‐emergent PN (67% vs. 40%), neutropenia (71% vs. 55%),
and febrile neutropenia (19% vs. 8%) than those in the ABVD arm.
More patients with an IPS of 4–7 in the A + AVD arm experi-
enced PN (69% vs. 45%), neutropenia (66% vs. 55%), and febrile
neutropenia (23% vs. 9%) than those in the ABVD arm.
PN was managed with dose modification and was generally
reversible. At a data cutoff of 15 October 2018 (median follow‐up,
36.1 months after end of treatment), PN resolution and improvement
rates had continued to increase in patients who were treated with
A + AVD or ABVD. At last follow‐up, the majority of patients with
Stage IV disease in the A + AVD arm (80%) and ABVD arm (85%) had
experienced resolution of or improvement in PN (Table 3); the pro-
portion of patients with resolution of or improvement in PN was
similar in the groups of patients with an IPS of 4–7. Consistent with
reports for the overall population, the rates of neutropenia and
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Time from randomization, months
HR, 0.711 (95% CI, 0.529-0.956)
P value = .023
















0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 32 34
Time from randomization, months
36 3830 42 44 46 4840 5250
425 420 415 413 408 407 403 397 388 374 336 302 280 224 194 171 126 95 79 39 27 20 4 3 3 0 0
421 410 404 399 390 388 384 377 369 358 329 286 258 200 163 146 110 82 66 35 24 10 5 2 1 0 0
HR, 0.507 (95% CI, 0.265-0.971)
P value = .037
Number of events: A+AVD = 14; ABVD = 26
(A)
(B)
F I GUR E 1 Kaplan–Meier estimates of (A) modified PFS per the IRF and (B) OS by treatment arm among patients with Stage IV disease at
primary analysis (data cutoff, 20 April 2017). Hazard ratios, 95% CIs, and p values from log‐rank tests are presented; circles indicate censored
data. A + AVD, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and
dacarbazine; CI, confidence interval; IRF, independent review facility; OS, overall survival; PFS, progression‐free survival
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received primary granulocyte colony‐stimulating factor (G‐CSF)
prophylaxis (Table S3). The use of primary G‐CSF prophylaxis is
recommended for all patients receiving the A + AVD combination.11
In the ABVD arm, pulmonary toxicity by standardized MedDRA
queries were reported in 27 of 413 patients (7%) with Stage IV dis-
ease and in 5% of patients with an IPS of 4–7 (Table S4). In the
A + AVD arm, pulmonary toxicity events by standardized MedDRA
queries were reported in eight of 424 patients (2%) with Stage IV
disease and two of 168 patients (1%) with an IPS of 4–7. Among
patients with Stage IV disease, deaths due to pulmonary toxicity
were reported in three of 413 patients who received ABVD and no
patients who received A + AVD.
In the overall ECHELON‐1 study population at a median follow‐
up of approximately 3 years, 34 patients developed secondary
malignancies, including 14 in the A + AVD arm (2.3%) and 20 in the
ABVD arm (3%). A total of three patients developed secondary AML
— two in the A + AVD arm and one in the ABVD arm. One patient
in the ABVD arm and none in the A + AVD arm developed sec-
ondary myelodysplastic syndrome. In the A + AVD arm, solid ma-
lignancies occurred in five patients and other hematologic
malignancies in five patients. In the ABVD arm, solid malignancies
occurred in six patients and hematologic malignancies in seven
patients. In patients with Stage IV disease, secondary malignancies
occurred in eleven of 425 patients (2.6%) in the A + AVD arm (four
solid and seven hematologic malignancies) and 14 of 421 patients
(3.3%) in the ABVD arm (five solid and nine hematologic malig-
nancies). Among patients with an IPS of 4–7, secondary malig-
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F I GUR E 2 Survival analyses in patients with an IPS of 4–7 at baseline by treatment arm at primary analysis (data cutoff, 20 April 2017).
Kaplan–Meier estimates of (A) PFS per the INV, and (B) OS. Hazard ratios, 95% CIs, and p values from log‐rank tests are presented; circles
indicate censored data. A + AVD, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin,
vinblastine, and dacarbazine; CI, confidence interval; INV, investigator; IPS, International Prognostic Score; OS, overall survival; PFS,
progression‐free survival
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hematologic malignancies) and 10 of 175 (5.7%; three solid and
seven hematologic malignancies) patients receiving A + AVD and
ABVD, respectively.
4 | DISCUSSION
Although cHL has a high 5‐year failure‐free survival rate of more
than 80% in all disease stages, patients with Stage IV disease treated
with ABVD have a comparatively lower 5‐year failure‐free survival
rate (76%).1,7,14,15 Similarly, patients with an IPS of 4–7 at diagnosis
often have a poor prognosis.16
The ECHELON‐1 trial showed a statistically significant
improvement in modified PFS by the IRF and additional improvement
in PFS per the investigator in patients with stage III or IV disease who
received A + AVD compared with those who received ABVD.12 In
this analysis, we focused on patients at a high risk of treatment
failure as indicated by baseline disease characteristics, including
Stage IV disease and an IPS of 4–7. This subgroup analysis included
additional efficacy (2‐year PFS, OS) and safety results and updated 3‐
year PFS in the context of the ITT population. The results demon-
strated that the value of adding BV to first‐line treatment for pa-
tients with advanced HL is greater in high‐risk patients and
demonstrated that high‐risk features may help all clinicians who treat
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 32 34
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HR, 0.723 (95% CI, 0.537-0.973)
P value = .032




F I GUR E 3 Updated survival analyses in patients with Stage IV disease by treatment arm (data cutoff, 15 October 2018). Kaplan–Meier
estimates of PFS per the INV. Hazard ratios, 95% CIs, and p values from log‐rank tests are presented; circles indicate censored data. A + AVD,
brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; CI,
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Subgroup ABVDA+AVD Hazard ratio (95% CI)
Event/N (%)
F I GUR E 4 Forest plot of hazard ratios for PFS per INV at 3 years for subgroups of patients with baseline Stage IV Hodgkin lymphoma
(data cutoff, 15 October 2018). INV, investigator; PFS, progression‐free survival
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advanced stage HL to predict poor treatment outcomes with stan-
dard ABVD, which can be partially overcome with the addition of BV.
At the primary analysis, an improvement was observed in the risk
of a modified PFS event in both high‐risk patients who received
A + AVD versus those who received ABVD. Furthermore, an
improvement in OS was noted in patients with Stage IV disease in
favor of A + AVD. The results of the primary analysis strongly sup-
ported the superiority of A + AVD over ABVD in patients with Stage
IV disease as well as those with a high IPS. The safety profile of
A + AVD observed in the two high‐risk subgroups was comparable to
that observed in the overall safety population, and no new safety
signals were identified. Importantly, patients with high‐risk cHL did
not experience an increased incidence or severity of AEs, consistent
with what was observed in the overall safety population.
Since the primary analysis, this patient population has also been
assessed at a median follow‐up of approximately 3 years. A previ-
ously published analysis of the ITT population at 3 years demon-
strated the durable benefit of A + AVD versus ABVD in patients
independent of age, disease stage, or risk‐factor score without
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HR, 0.588 (95% CI, 0.386-0.894)
P value = .012
Number of events: A+AVD = 35; ABVD = 58
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F I GUR E 5 Kaplan–Meier estimates of PFS per the INV by treatment arm at 3 years for patients with IPS of 4–7 (data cutoff, 15 October
2018). Hazard ratios, 95% CIs, and p values from log‐rank tests are presented; circles indicate censored data. A + AVD, brentuximab vedotin
plus doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; CI, confidence interval; INV,
investigator; IPS, International Prognostic Score; PFS, progression‐free survival
TAB L E 2 AEs reported in patients
with Stage IV Hodgkin lymphoma
AE, n (%) A + AVD (n = 424) ABVD (n = 413)
Any AE 416 (98) 403 (98)
Drug‐related AE 408 (96) 383 (93)
Grade ≥3 AE 352 (83) 278 (67)
Drug‐related grade ≥3 AE 336 (79) 250 (61)
Serious AE 170 (40) 114 (28)
Drug‐related serious AE 140 (33) 83 (20)
AE resulting in study drug or dose discontinuation 44 (10) 66 (16)
AE resulting in dose modificationa 268 (63) 184 (45)
Dose held 26 (6) 22 (5)
Dose interrupted 12 (3) 20 (5)
Dose reduced 121 (29) 41 (10)
Dose delayed 204 (48) 138 (33)
On‐study death 5 (1) 8 (2)
Death due to drug‐related AE 5 (1) 5 (1)
Abbreviations: A + AVD, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD,
doxorubicin, bleomycin, vinblastine, and dacarbazine; AE, adverse event.
aTable is based on the number of patients, and one patient might have multiple AEs.
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analysis of patients with Stage IV disease, an analysis of PFS by
investigator demonstrated an improvement that was maintained at 3
years with A + AVD versus ABVD, with a reduction in the risk of a PFS
event of 28% (HR, 0.723; 95% CI, 0.537–0.973). In addition, benefit
based on PFS per investigator assessment in patients with an IPS of 4–
7 was also maintained at a median follow‐up of 3 years (HR, 0.588;
95%CI, 0.386–0.894).13 These updated results are consistent with the
results of the primary analysis and further support the use of A + AVD
as a meaningful treatment option for patients with high‐risk cHL.
Upon treatment outcome being stratified in patients with Stage
IV disease according to PET2 status, both PET2‐negative and PET2‐
positive cohorts had a better outcome in the experimental versus the
standard arm (HR, 0.732; 95% CI 0.520–1.031 for PET2‐negative
patients; HR, 0.727; 95% CI, 0.366–1.445 for PET2‐positive patients).
PET‐2‐negative and PET‐2‐positive cohorts with IPS 4–7 also had a
better outcome in the experimental versus the standard arms (HR,
0.545; 95% CI, 0.331–0.898 in PET2‐negative patients; HR, 0.510;
95% CI, 0.190–1.365 in PET2‐positive patients).
In recent years, multiple clinical trials, including SWOG S0816,
RATHL, and GITIL/FIL HD 0607, have focused on improving out-
comes in patients with advanced stage cHL by managing patients
who are initiated on ABVD and have a positive PET2 result with
escalation of therapy to BEACOPPesc.17–19 The comparison of
ECHELON‐1 with studies of BEACOPPesc or PET response–adapted
BEACOPPesc‐based regimens is difficult because of important dif-
ferences in inclusion criteria (different proportions of patients with
stage II disease, different age ranges), PET interpretation rules, and
study endpoints (PFS vs. modified PFS). In addition, although the use
of BEACOPPesc has shown superior 3‐ and 5‐year PFS compared
with standard ABVD in PET2‐positive patients, it comes at the cost of
increased short‐ and long‐term toxicities, including infertility and
secondary malignancies.4 In the primary SWOG S0816 study,
secondary malignancies were observed in 6% of PET2‐positive pa-
tients receiving BEACOPPesc or BEACOPP‐14 with 3.3 years of
follow‐up, and the rate increased to 14% with 5.9 years of follow‐
up.17 In the RATHL and HD0607 trials, the rate of secondary ma-
lignancies was lower, but the follow‐up in these two studies was
shorter.16,17 In ECHELON‐1, the rate of secondary malignancies on
the A + AVD arm was 2.8% (Stage IV, 2.6%; IPS of 4–7, 3.3%) and 3%
in the ABVD arm (Stage IV, 3.3%; IPS of 4–7, 5.7%). Although follow‐
up is ongoing, these secondary malignancy data from ECHELON‐1
suggest that the rate with A + AVD did not exceed that with ABVD;
hence, A + AVD could provide an effective alternative to BEA-
COPPesc that could potentially spare patients the associated long‐
term toxicities.
One notable limitation to these analyses is that although these
subgroups were prespecified, they were not alpha‐controlled; thus, p
values cannot be adjusted for inferential purposes. Additionally,
there is a potential for a close interaction between subgroups to
confound the observed treatment benefit. For example, the presence
of Stage IV disease is one of the seven risk factors included in the IPS,
resulting in a higher chance that a patient will be in both subgroups.20
Overlapping of other risk factors, such as extranodal involvement,
advanced age, or subtype, may also exist. It is therefore difficult to
ascertain the exact attribute or attributes that determine greater
benefit with A + AVD.
In ECHELON‐1, A + AVD provided clinically meaningful im-
provements in modified PFS, with an acceptable safety profile, sup-
porting a favorable benefit‐risk balance in the first‐line treatment of
adult patients with cHL, including those with Stage IV disease or an
IPS of 4–7. With continued follow‐up of PFS per investigator, a
consistent benefit with A + AVD over ABVD has been observed
across prespecified subgroups, including patients with high‐risk
characteristics.
TAB L E 3 PN resolution in Stage IV patients (median follow‐up, 36.1 months postend of treatment)
Outcome of PN events at last follow‐up, n (%) A + AVD (n = 283) ABVD (n = 165) Total (N = 448)
Maximum severity grades, n (%)
1 58 (20) 27 (16) 85 (19)
2 30 (11) 14 (8) 44 (10)
3 9 (3) 3 (2) 12 (3)
4 1 (<1) 0 1 (<1)
Resolutiona of or improvementb in PN events 225 (80) 140 (85) 365 (81)
Resolutiona of all PN events 185 (65) 121 (73) 306 (68)
Improvementb in PN events 40 (14) 19 (12) 59 (13)
No resolution of or improvement in any PN events 58 (20) 25 (15) 83 (19)
Abbreviations: A + AVD, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and
dacarbazine; PN, peripheral neuropathy.
aDefined as event outcome of “resolved” or “resolved with sequelae.”
bResolution implies improvement. In addition, for events that were not resolved, improvement was defined as decrease by ≥1 grade from the worst
grade, with no higher grade thereafter.
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